(−)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo

Predictors of breast cancer cell types and their prognostic power in breast cancer patients

(2018) Fan Wang et al.   BMC GENOMICS

The Biological Activities of Oleocanthal from a Molecular Perspective

(2018) Kok-Lun Pang et al.   Nutrients

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface

(2018) Jeroen Claus et al.   eLife

The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment

(2017) Nehad M. Ayoub et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody

(2017) Andres Lopez-Albaitero et al.   OncoImmunology

The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance

(2016) Katarzyna Miekus   ONCOLOGY REPORTS

The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor

(2016) Mohamed M. Mohyeldin et al.   Oncotarget

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy

(2015) M. Giuliano et al.   CLINICAL CANCER RESEARCH

Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1.

(2015) Janghee Woo et al.   Gastroenterology Report

Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside

(2014) A. Furlan et al.   CANCER RESEARCH

Oleocanthal, a Phenolic Derived from Virgin Olive Oil: A Review of the Beneficial Effects on Inflammatory Disease

(2014) Lisa Parkinson et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies

(2014) Simonetta M. Leto et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Olive Phenolics as c-Met Inhibitors: (-)-Oleocanthal Attenuates Cell Proliferation, Invasiveness, and Tumor Growth in Breast Cancer Models

(2014) Mohamed R. Akl et al.   PLoS One

Treatment of HER2-positive breast cancer

(2013) Maria Cristina Figueroa-Magalhães et al.   BREAST

EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis

(2013) J. L. Breindel et al.   CANCER RESEARCH

Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer

(2012) M. S. N. Mohd Sharial et al.   ANNALS OF ONCOLOGY

Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer

(2012) Ana M. Gonzalez-Angulo et al.   CANCER

MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells

(2012) C.-T. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Differential roles of trans-phosphorylated EGFR, HER2, HER3 and RET as heterodimerisation partners of MET in lung cancer with MET amplification

(2011) J Tanizaki et al.   BRITISH JOURNAL OF CANCER

Synergistic Effects of Foretinib with HER-Targeted Agents in MET and HER1- or HER2-Coactivated Tumor Cells

(2011) L. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Treatment of HER2-positive breast cancer: current status and future perspectives

(2011) Carlos L. Arteaga et al.   Nature Reviews Clinical Oncology

HGF-independent potentiation of EGFR action by c-Met

(2011) A M Dulak et al.   ONCOGENE

(−)-Oleocanthal as a c-Met Inhibitor for the Control of Metastatic Breast and Prostate Cancers

(2011) Ahmed Elnagar et al.   PLANTA MEDICA

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease

(2010) Rena Callahan et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis

(2010) Okkyung Rho et al.   MOLECULAR CARCINOGENESIS

Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

(2009) W. Scheuer et al.   CANCER RESEARCH

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer

(2009) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression

(2009) X. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer

(2009) M. G. Ponzo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

(2008) D. L. Shattuck et al.   CANCER RESEARCH

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations

(2008) S. Yano et al.   CANCER RESEARCH

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases

(2008) P MEDINA et al.   CLINICAL THERAPEUTICS